Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira Biosciences Inc (NASDAQ:PCRX) Given Consensus Rating of "Buy" by Analysts
06:24am, Thursday, 23'rd Apr 2020
Pacira Biosciences Inc (NASDAQ:PCRX) has been assigned an average recommendation of “Buy” from the eighteen analysts that are currently covering the stock, Marketbeat reports. Seven research analy
Stifel Nicolaus Keeps a Buy Rating on Principia Biopharma (PRNB)
08:00am, Wednesday, 22'nd Apr 2020
Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Principia Biopharma (PRNB) on April 17. The company's shares closed last Tuesday at
Stifel Nicolaus Keeps a Buy Rating on Principia Biopharma (PRNB)
08:00am, Wednesday, 22'nd Apr 2020
Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Principia Biopharma (PRNB – Research Report) on April 17. The
Esperion (ESPR) Received its Third Buy in a Row
04:33pm, Monday, 20'th Apr 2020
After Needham and Merrill Lynch gave Esperion (NASDAQ: ESPR) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus.
Esperion (ESPR) Received its Third Buy in a Row
04:33pm, Monday, 20'th Apr 2020
After Needham and Merrill Lynch gave Esperion (NASDAQ: ESPR) a Buy rating last month, the company received another Buy, this
Zacks: Analysts Expect Pacira Biosciences Inc (NASDAQ:PCRX) Will Post Earnings of $0.35 Per Share
09:32am, Monday, 20'th Apr 2020
Equities research analysts expect that Pacira Biosciences Inc (NASDAQ:PCRX) will report earnings per share of $0.35 for the current quarter, according to Zacks Investment Research. Nine analysts have
Zacks: Brokerages Anticipate Pacira Biosciences Inc (NASDAQ:PCRX) Will Post Quarterly Sales of $103.10 Million
05:56am, Sunday, 19'th Apr 2020
Equities research analysts expect Pacira Biosciences Inc (NASDAQ:PCRX) to report $103.10 million in sales for the current quarter, Zacks reports. Nine analysts have issued estimates for Pacira Bioscie
Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row
12:33pm, Friday, 17'th Apr 2020
After Leerink Partners and Piper Sandler gave Pacira Pharmaceuticals (NASDAQ: PCRX) a Buy rating last month, the company received another Buy, this time
Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row
12:33pm, Friday, 17'th Apr 2020
After Leerink Partners and Piper Sandler gave Pacira Pharmaceuticals (NASDAQ:
PCRX
) a Buy rating last month, the company received another Buy, this time from Barclays. Analyst
Balaji Prasad
maintaine
Pacira Pharmaceuticals (PCRX) Receives a Buy from Northland Securities
11:38am, Friday, 17'th Apr 2020
Northland Securities analyst Tim Chiang maintained a Buy rating on Pacira Pharmaceuticals (PCRX) today and set a price target of $50.00. The company's
Pacira Pharmaceuticals (PCRX) Receives a Buy from Northland Securities
11:38am, Friday, 17'th Apr 2020
Northland Securities analyst
Tim Chiang
maintained a
Buy
rating on Pacira Pharmaceuticals (
PCRX
–
Research Report
) today and set a price target of
$50.00
. The company’s shares closed last Thurs
StartUPDATES: New developments for healthcare startups
11:30am, Friday, 17'th Apr 2020
Read about new developments at the Airbnb of medical office and surgery center space, HealCo, investment news, and more.
Barclays Remains a Sell on Teva Pharmaceutical Industries (TEVA)
07:01am, Friday, 17'th Apr 2020
Barclays analyst Balaji Prasad maintained a Sell rating on Teva Pharmaceutical Industries (TEVA) yesterday and set a price target of $9.00. The company's
Barclays Remains a Sell on Teva Pharmaceutical Industries (TEVA)
07:01am, Friday, 17'th Apr 2020
Barclays analyst
Balaji Prasad
maintained a
Sell
rating on Teva Pharmaceutical Industries (
TEVA
–
Research Report
) yesterday and set a price target of
$9.00
. The company’s shares closed last Th
Bausch Health Companies (BHC) Gets a Buy Rating from Barclays
07:01am, Friday, 17'th Apr 2020
In a report released yesterday, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC), with a price target of $28.00. The
